Nemaura launches direct to consumer offering of metabolic health program

Nemaura Medical announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring with its behavioral change program, Miboko, complemented by pharmaceutical interventions using GLP-1 agonists such as Ozempic, Wegovy and Mounjaro. This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets. “The launch of this integrated program is a turning point in the Company’s history. Leveraging off positive outcomes observed thus far from the NHS studies, and the profound impact of GLP-1 therapy globally leads us to believe we have an optimal offering, with the goal of enabling the drugs to help kick start weight loss initiatives and then sustain this through education and sustainable behavioural change,” said Dr Faz Chowdhury, CEO of Nemaura. Users may now subscribe directly via the Miboko website at www.Miboko.com